371944-46-6Relevant articles and documents
Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE
Guo, Shanchun,He, Ling,Luo, Lan,Wang, Guangdi,Zhang, Changde,Zhang, Qiang,Zheng, Shilong,Zhong, Qiu
, (2020/05/22)
PI-103 (7) is a potent dual phosphatidylinositol 3-kinase (PI3K)/mTOR inhibitor, but its rapid in vivo metabolism hinders its further clinical development. To improve the bioavailability of PI-103, we designed and synthesized a PI-103 bioisostere, PI-103B
Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors
Hayakawa, Masahiko,Kaizawa, Hiroyuki,Moritomo, Hiroyuki,Koizumi, Tomonobu,Ohishi, Takahide,Yamano, Mayumi,Okada, Minoru,Ohta, Mitsuaki,Tsukamoto, Shin-ichi,Raynaud, Florence I.,Workman, Paul,Waterfield, Michael D.,Parker, Peter
, p. 2438 - 2442 (2008/02/05)
4-Morpholin-4-ylpyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine 2a was discovered in our chemical library as a novel p110α inhibitor with an IC50 of 1.4 μM. By structural modification of 2a, the 2-aryl-4-morpholinopyrido[3′,2′:4,5]furo[3,2-d]pyrimidin